Table 1.
Demographics and baseline characteristics
| Demographic/baseline characteristic | Total population n = 679 | BBFC n = 218 | Brinzolamide n = 229 | Brimonidine n = 232 |
|---|---|---|---|---|
| Age, years | ||||
| Mean ± standard deviation | 64.9 ± 10.4 | 65.7 ± 10.3 | 64.2 ± 10.3 | 64.9 ± 10.5 |
| <65, n (%) | 323 (47.6%) | 98 (45.0%) | 110 (48.0%) | 115 (49.6%) |
| ≥65, n (%) | 356 (52.4%) | 120 (55.0%) | 119 (52.0%) | 117 (50.4%) |
| Race, n (%) | ||||
| White | 529 (77.9%) | 174 (79.8%) | 179 (78.2%) | 176 (75.9%) |
| Black | 130 (19.1%) | 36 (16.5%) | 42 (18.3%) | 52 (22.4%) |
| Asian | 9 (1.3%) | 3 (1.4%) | 5 (2.2%) | 1 (0.4%) |
| Multiracial | 3 (0.4%) | 0 (0%) | 1 (0.4%) | 2 (0.9%) |
| Other | 8 (1.2%) | 5 (2.3%) | 2 (0.9%) | 1 (0.4%) |
| Gender, n (%) | ||||
| Male | 298 (43.9%) | 100 (45.9%) | 97 (42.4%) | 101 (43.5%) |
| Female | 381 (56.1%) | 118 (54.1%) | 132 (57.6%) | 131 (56.5%) |
| Diagnosis, n (%) | ||||
| Ocular hypertension | 168 (24.7%) | 51 (23.4%) | 59 (25.8%) | 58 (25.0%) |
| Open-angle glaucoma | 511 (75.3%) | 167 (76.6%) | 170 (74.2%) | 172 (75.0%) |
Note: Reprinted with permission from Nguyen QH, McMenemy MG, Realini T, et al. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther. 2013;29:290–297.6
Abbreviation: BBFC, brinzolamide-brimonidine fixed combination.